Grifols becomes the great protagonist of Ibex 35, with a strong rise in the stock market. The Hemoderivated Company, which has come to touch a cross of 9.35 euros (+14.9%), rises to half a session by 7.18% to 8.72 euros.
The Canadian Investment Fund Brookfield has resumed conversations about a possible acquisition From the Hemodervados company four months after a previous attempt, the news website reported on Wednesday The confidentialwhich is based on sources in the unidentified sector.
According to these sources, Tristan Tully, general director of Brookfield, is holding conversations with the Grifols family. The intention of the Canadian fund would be considering making an offer to value the company in 7,000 million euros. Would be advised by Morgan Stanley.
This is a second attempt, after Brookfield withdraw a non -binding offer after the Grifols Council rejected the offer because it considers it too low and recommended to the shareholders to maintain their actions.
The offer price was 10.5 euros per sharewhat the company valued at about 6.7 billion dollars.
However, the enthusiasm in the stock market has stopped a little after the company has sent a statement to the National Securities Market Commission (CNMV) in which he assures that, “in relation to a possible new offer for the actions of Grifols by Brookfield Capital Partners (UK) Limited, the company informs that Your Board of Directors has no knowledge about this information”.
Despite today’s rise, Grifols’s actions still fall 23% since in November last year they touched the 11.35 euros. However, they rise 12.2% from their minimum of the last 52 weeks, located at 7.77 euros since June 27 of last year.
Fundamental analysts give him a 87% bullish potential to valuewith a majority recommendation of ‘Buy’ and an average target price of 16.31 euros, according to the data collected by Reuters.